Rinvoq Insurance Denial Appeal Guide

Why Rinvoq Gets Denied

Rinvoq is a newer JAK inhibitor that costs over $5,000/month. Insurance companies prefer that patients try older, cheaper biologics first. Step therapy requirements are the primary barrier to coverage.

Common Denial Reasons

• Step therapy not completed (must fail TNF inhibitors first)
• Prior authorization missing or incomplete
• Diagnosis not on the approved indication list
• Preferred alternative available on formulary
• Quantity limits exceeded

How to Appeal

1. Document all failed medications — dates, duration, side effects, and outcomes
2. Get specialist documentation — rheumatologist or dermatologist letter explaining why Rinvoq is medically necessary
3. Reference clinical guidelines — ACR guidelines support JAK inhibitors after conventional DMARD failure
4. Submit appeal with peer-reviewed evidence supporting Rinvoq for your specific condition
5. Request peer-to-peer review if initial appeal fails

Required Documentation

• Complete medication history with dates and reasons for discontinuation
• Lab results (inflammatory markers, disease activity scores)
• Specialist letter of medical necessity
• Clinical trial data supporting Rinvoq for your condition